Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY
Benzinga
Sep 26, 2024
For the year six month period ended June 30
Note
2024
unaudited
£'000
2023
unaudited
£'000
Revenue
-
298
Research and development costs
(2,189)
(2,251)
Administrative costs
(2,034)
(2,291)
Loss from operations
(4,223)
(4,244)
Finance income
3
839
410
Finance expense
3
(49)
(22)
Loss before tax
(3,433)
(3,856)
Taxation
4
125
288
Loss for the period attributable to the owners of the parent
(3,308)
(3,568)
Total comprehensive loss attributable to the owners of the parent
(3,308)
(3,568)
Loss per share
Basic and diluted loss per ordinary share – pence
5
(0.1p)
(3.6)p
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.